Company Filing History:
Years Active: 2010-2016
Title: Lance Howard Leopold: Innovator in Leukemia Treatment
Introduction
Lance Howard Leopold is a notable inventor based in Dresher, PA (US). He has made significant contributions to the field of oncology, particularly in the treatment of various forms of leukemia. With a total of 2 patents, his work focuses on innovative therapeutic approaches that aim to improve patient outcomes.
Latest Patents
Lance's latest patents include groundbreaking inventions in the treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). His first patent relates to JAK selective inhibitors for use in treating these conditions in patients. The second patent presents methods of treatment and pharmaceutical combinations for acute leukemia and myelodysplastic syndrome. This invention employs an anti-CD33 cytotoxic conjugate in combination with compounds such as anthracyclines and nucleoside analogs, with preferred methods utilizing gemtuzumab ozogamicin, daunorubicin, and cytarabine.
Career Highlights
Throughout his career, Lance has worked with prominent companies in the pharmaceutical industry, including Incyte Corporation and Wyeth. His experience in these organizations has allowed him to develop and refine his innovative approaches to leukemia treatment.
Collaborations
Lance has collaborated with esteemed colleagues such as Albert Assad and Jay Marshall Feingold. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Lance Howard Leopold's contributions to leukemia treatment through his innovative patents highlight his dedication to improving patient care. His work continues to influence the field of oncology and offers hope for better therapeutic options for patients suffering from these challenging conditions.